Imaging tumor hypoxia: Blood-borne delivery of imaging agents is fundamentally different in hypoxia subtypes

Peter Vaupel; Arnulf Mayer

doi:10.1142/s179354581330005x

[1] P. Vaupel, A. Mayer, M. H€ockel, "Tumor hypoxia and malignant progression," Methods Enzymol. 381, 335–354 (2004).

[2] P. Vaupel, M. H€ockel, A. Mayer, "Detection and characterization of tumor hypoxia using pO2 histography," Antioxid. Redox. Signal. 9, 1221–1235 (2007).

[3] P. Vaupel, A. Mayer, "Hypoxia in cancer: Signifi- cance and impact on clinical outcome," Cancer Metastasis Rev. 26, 225–239 (2007).

[4] M. H€ockel, C. Knoop, K. Schlenger, B. Vorndran, E. Baussmann,M. Mitze, P. G. Knapstein, P. Vaupel, "Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix," Radiother. Oncol. 26, 45–50 (1993).

[5] M. H€ockel, K. Schlenger, B. Aral, M. Mitze, U. Sch ffer, P. Vaupel, "Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix," Cancer Res. 56, 4509– 4515 (1996).

[6] A. Mayer, P. Vaupel, "Hypoxia, lactate accumulation, and acidosis: Siblings or accomplices driving tumor progression and resistance to therapy " Adv. Exp. Med. Biol. 789, 203–209 (2013).

[7] M. R. Horsman, L. S. Mortensen, J. B. Petersen, M. Busk, J. Overgaard, "Imaging hypoxia to improve radiotherapy outcome," Nat. Rev. Clin. Oncol. 9, 674–687 (2012).

[8] A. R. Padhani, K. A. Krohn, J. S. Lewis, M. Alber, "Imaging oxygenation of human tumours," Eur. Radiol. 17, 861–872 (2007).

[9] S. T. Astner, K. Shi, P. Vaupel, M. Molls, "Imaging of tumor physiology: Impacts on clinical radiation oncology," Exp. Oncol. 32, 149–152 (2010).

[10] F. C. Gaertner, M. Souvatzoglou, G. Brix, A. J. Beer, "Imaging of hypoxia using PET and MRI," Curr. Pharm. Biotechnol. 13, 552–570 (2012).

[11] J. L. Tatum, G. J. Kelloff, R. J. Gillies, J. M. Arbeit, J. M. Brown, K. S. Chao, J. D. Chapman, W. C. Eckelman, A. W. Fyles, A. J. Giaccia, R. P. Hill, C. J. Koch, M. C. Krishna, K. A. Krohn, J. S. Lewis, R. P. Mason, G. Melillo, A. R. Padhani, G. Powis, J. G. Rajendran, R. Reba, S. P. Robinson, G. L. Semenza, H. M. Swartz, P. Vaupel, D. Yang, B. Croft, J. Hoffman, G. Liu, H. Stone, D. Sullivan, "Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy," Int. J. Radiat. Biol. 82, 699–757 (2006).

[12] R. H. Thomlinson, L. H. Gray, "The histological structure of some human lung cancers and the possible implications for radiotherapy," Br. J. Cancer 9, 539–549 (1955).

[13] J. M. Brown, "Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation," Br. J. Radiol. 52, 650–656 (1979).

[14] D. J. Chaplin, R. E. Durand, P. L. Olive, "Acute hypoxia in tumors: Implications for modifiers of radiation effects," Int. J. Radiat. Oncol. Biol. Phys. 12, 1279–1282 (1986).

[15] C. Bayer, K. Shi, S. T. Astner, C. A. Maftei, P. Vaupel, "Acute versus chronic hypoxia: Why a simplified classification is simply not enough," Int. J. Radiat. Oncol. Biol. Phys. 80, 965–968 (2011).

[16] C. Bayer, P. Vaupel, "Acute versus chronic hypoxia in tumors: Controversial data concerning time frames and biological consequences," Strahlenther. Onkol. 188, 616–627 (2012).

[17] C. A. Maftei, C. Bayer, K. Shi, S. T. Astner, P. Vaupel, "Quantitative assessment of hypoxia subtypes in microcirculatory supply units of malignant tumors using (immuno-)fluorescence techniques," Strahlenther. Onkol. 187, 260–266 (2011).

[18] P. Vaupel, A. Mayer, "Hypoxia in tumors: Pathogenesis- related classification, characterization of hypoxia- subtypes, and associated biological and clinical implications," Adv. Exp. Med. Biol., in press (2014).

[19] S. Matsumoto, H. Yasui, J. B. Mitchell, M. C. Krishna, "Imaging cycling tumor hypoxia," Cancer Res. 70, 10019–10023 (2010).